Loading...
India's paclitaxel imports from BULGARIA total $19.5K across 3 shipments from 1 foreign suppliers. RX SOLUTION LIMITED leads with $19.5K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include AMNEAL PHARMACEUTICALS PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for paclitaxel — a concentrated sourcing relationship with select suppliers from BULGARIA.
RX SOLUTION LIMITED is the leading Paclitaxel supplier from BULGARIA to India, with import value of $19.5K across 3 shipments. The top 5 suppliers — RX SOLUTION LIMITED — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | RX SOLUTION LIMITED | $19.5K | 3 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | AMNEAL PHARMACEUTICALS PRIVATE LIMITED | $19.5K | 3 | 100.0% |
BULGARIA → India trade corridor intelligence
The Bulgaria to India trade corridor is currently stable. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently, with minimal congestion. Freight rates have remained consistent over the past year. The exchange rate between the Bulgarian Lev and the Indian Rupee is favorable for trade, enhancing the competitiveness of Bulgarian exports.
The Indian government's PLI scheme aims to boost domestic manufacturing, which may impact the volume of finished formulation imports, including those from Bulgaria. Import substitution policies are being considered to reduce dependency on foreign imports, potentially affecting future trade dynamics.
India and Bulgaria maintain a cordial trade relationship, with ongoing discussions to enhance pharmaceutical trade. There are no existing Free Trade Agreements (FTAs), but mutual recognition of Good Manufacturing Practices (GMP) is under consideration to facilitate smoother trade. Pharmaceutical trade facilitation measures are being explored to strengthen bilateral ties.
The FOB price from Bulgaria is $19,500 for the 3 shipments. Freight and insurance costs are estimated at $1,500. The Basic Customs Duty amounts to $2,000 (10% of $20,000). The Social Welfare Surcharge is $240 (12% of $2,000). The IGST is $2,400 (10% of $24,000). Port handling and Customs House Agent (CHA) charges total $500. The total landed cost per unit is approximately $8,000.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Paclitaxel into India, the foreign manufacturer must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). The product must be registered with the Central Drugs Standard Control Organisation (CDSCO) by submitting Form 40 or 41, along with a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare. The registration process includes providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for import drug registration varies but typically ranges from 6 to 12 months. Paclitaxel formulations under HS Code 30049044 are subject to these requirements.
Imported batches of Paclitaxel formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, including studies conducted under ICH Zone IV conditions, must be provided. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the product.
Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of finished pharmaceutical formulations, including Paclitaxel. The Production Linked Incentive (PLI) scheme has been expanded to encourage domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements between India and Bulgaria have facilitated smoother trade procedures, but compliance with updated regulatory standards remains essential.
Market demand, customs duty structure, and competitive landscape · Import duty: 10%
India imports finished Paclitaxel formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic manufacturing capacity for certain Paclitaxel formulations is limited, leading to a reliance on imports. The market size for Paclitaxel formulations in India is substantial, with a growing number of patients requiring cancer treatment.
The Basic Customs Duty for HS Code 30049044 is 10%. The Social Welfare Surcharge (SWS) is levied at 12% of the Basic Duty. The Integrated Goods and Services Tax (IGST) is applicable at 10% on the total value, including customs duties. Anti-dumping duties are not currently imposed on Paclitaxel formulations. Exemption notifications are not applicable for imports from Bulgaria. The total landed duty percentage is approximately 32.4%.
India sources finished Paclitaxel formulations from Bulgaria due to the availability of patented formulations and specialized dosage forms not produced domestically. Bulgaria's competitive advantage lies in its adherence to international quality standards and GMP compliance. Other suppliers include China, Germany, and the United States, but Bulgaria's share in the Indian market is growing due to these advantages.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished Paclitaxel formulations from Bulgaria due to the availability of patented formulations and specialized dosage forms not produced domestically. Bulgaria's adherence to international quality standards and GMP compliance ensures the reliability of the products. Specific formulations supplied by Bulgaria, such as certain injection dosages, are not manufactured in India, necessitating imports.
Compared to China, Germany, and the United States, Bulgaria offers competitive pricing and high-quality products. Bulgaria's regulatory compliance and GMP adherence provide a unique advantage in the Indian market. While other countries may offer similar products, Bulgaria's focus on quality and specialized formulations makes it a preferred choice for Indian importers.
Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. There have been no significant shortages reported in the past, but monitoring the supply chain is essential to mitigate these risks.
Import license checklist, document requirements, quality testing, and compliance
Upon arrival, customs drug inspectors will collect samples for mandatory batch testing. The process includes sample collection, testing, and certification, which may take several weeks. If a batch fails quality testing, it may be rejected, leading to delays or additional costs. Common quality issues from Bulgaria have been minimal, but adherence to Indian standards is crucial
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Paclitaxel suppliers from BULGARIA to India include RX SOLUTION LIMITED. The leading supplier is RX SOLUTION LIMITED with import value of $19.5K USD across 3 shipments. India imported Paclitaxel worth $19.5K USD from BULGARIA in total across 3 shipments.
India imported Paclitaxel worth $19.5K USD from BULGARIA across 3 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Paclitaxel sourced from BULGARIA include AMNEAL PHARMACEUTICALS PRIVATE LIMITED. The largest buyer is AMNEAL PHARMACEUTICALS PRIVATE LIMITED with $19.5K in imports across 3 shipments.
The total value of Paclitaxel imports from BULGARIA to India is $19.5K USD, across 3 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists